---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-298525"
form_type: "8-K"
ticker: "MCRB"
cik: "0001609809"
company_name: "Seres Therapeutics, Inc."
filed_at: "2026-07-08T20:05:18+00:00"
generated_at: "2026-07-08T20:06:12.242917+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Seres Therapeutics stockholders approve 900k share increase to 2025 Incentive Award Plan

## Summary
- Stockholders approved amendment to 2025 Incentive Award Plan, increasing shares available by 900,000.
- Three Class II directors elected: Stephen A. Berenson, Claire M. Fraser, Ph.D., Richard N. Kender.
- Advisory vote on executive compensation passed with 3,374,813 for, 620,353 against.
- Ratification of PwC as auditor for FY2026 approved with 4,542,915 for, 267,601 against.
- Meeting had 51.75% quorum (4,985,176 shares represented).

## SEC filing metadata
- accession: 0001193125-26-298525
- form_type: 8-K
- ticker: MCRB
- cik: 0001609809
- company_name: Seres Therapeutics, Inc.
- filed_at: 2026-07-08T20:05:18+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1609809/000119312526298525/0001193125-26-298525-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1609809/000119312526298525/d100733d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-298525
- JSON: https://secwatch.observer/filing/0001193125-26-298525.json
- Plain text: https://secwatch.observer/filing/0001193125-26-298525.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.